Project Lead
Seed Stage
Project Lead
Pre-Seed Stage
Project Lead
Pre-Seed Stage
Project Lead
Seed Stage
The current invasive surgical treatment for ascending aortic aneurisms is very high risk with up to 80% mortality rates.
Developing the first non-invasive device for the treatment of ascending aorta aneurisms and dissections, which is a deadly heart condition.
Market size: $1.7B
Non-dilutive funding approved $1M
M&A in 2027: $350M
Project Lead
Pre-Seed Stage
Sensitive and specific diagnostic, imaging and therapeutic options for deadly cancers like glioblastoma do not exist.
Highly targeted, stable aptamers allow us to bind glioblastoma stem cells, and will lead to screening blood tests, theragnostics and payload delivery for better outcomes.
Market size: $4.2B (by 2028)
M&A in 2028: $450M
Project Lead
Pre-Seed Stage
60% post ischemic stroke treatment disability.
Developing the first device to treat ischemic stroke in first pass (time saving = reduced mortality/disability rates) and more effectively (targeting soft, medium, and hard clots that currently are an unmet need).
Market size: $1B (by 2028)
M&A in 2027: $350M
Get the latest news about
medtech and investments.